Exercise of Options and Total Voting Rights

RNS Number : 2212M

Redx Pharma plc

11 October 2016

 

11 October 2016

AIM: REDX

 REDX PHARMA PLC

("Redx" or "the Company")

Exercise of Options and Total Voting Rights

Redx, the drug development company, announces that it has received notice from employees of the Company to exercise share options over an aggregate of 145,319 ordinary shares of 1p each in the Company ("Ordinary Shares"). The exercise price is 50p for 110,025 Ordinary Shares and 42.5p for the remaining 35,294 Ordinary Shares.

Application has been made for the 145,319 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will commence on 17 October 2016. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 93,697,957. Accordingly, the figure of 93,697,957 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Broker)	T: [phone]
Phil Davies/ Michael Reynolds
KTZ Communications	T: [phone]
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhea, bone tumours, skin, brain, breast, pancreatic and blood cancers.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

END

 

 

IOEGGGGWUUPQURG